THE FIRST ON-LINE DRAFT OF HUMAN PHEOCHROMOCYTOMA/PARAGANGLIOMA PROTEOME
Pheochromocytoma and paraganglioma (PHEO/PGL) are rare neuroendocrine tumors arising from chromaffin cells of adrenal medulla and from extra-adrenal sympathetic and parasympathetic ganaglia, respectively. Low incidence (0.8 per 100 000) classifies PHEO/PGL among rare diseases. The majority of PHEO/PGL are benign, yet show high morbidity and mortality due to excessive production of catecholamines, leading to hypertension, arrhythmia and stroke. Up to 25 percent are malignant. Therapy for patients with metastatic PHEO/PGL is limited with 5 year survival often less than 50 percent.
Pilot quantitative analysis of human pheochormocytoma and paraganglioma sample (5797 proteins). LC-MS/MS analysis of 3 individual tumor samples. We
used iTRAQ labeling with 4 labels and analyzed 2 different PHEO and 1 sympathetic PGL sample provided by our partner (Karel Pacak, NICHD-NIH, Bethesda, MD). Healthy
adrenal medulla was used as a control . We identified
over 5700 proteins/protein groups with FDR 0.01. Of those 4400 were identified
with 2 or more unique peptides, each with at least 0,95% confidence.